Seres Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Seres Therapeutics, Inc. (MCRB), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are MCRB insiders buying or selling?
In the last 12 months, Seres Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 16 sales ($54.9K) — net selling of $54.9K. Since January 2018, Trabud has recorded 96 Form 4 filings for MCRB: 2 buys ($47.5M) and 94 sells ($6.0M).
Source: SEC EDGAR Form 4
What stands out
- No Seres Therapeutics, Inc. insider made an open-market purchase in the last 12 months; the 16 reported open-market sales totaled $54.9K.
Key Statistics (January 2018 – Aug 18, 2026)
Total Form 4 filings
96
SEC EDGAR
Insider filers
16
Insider buys (2)
$47.5M
Insider sells (94)
$6.0M
Insider sentiment
Net buyingNet insider flow of $41.5M in net buying since January 2018, and $54.9K in net selling over the last 12 months.
Recent MCRB insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Kelly Brady | EVP, Chief Operating Officer | Sale | 64 | $4.55 | $291.2 | SEC ↗ |
| Aug 18, 2026 | Eric D. Shaff | Director | Sale | 263 | $4.55 | $1.2K | SEC ↗ |
| Aug 18, 2026 | Matthew R Henn | President and Chief Scientific Officer | Sale | 81 | $4.55 | $368.55 | SEC ↗ |
| Aug 18, 2026 | Thomas Desrosier | EVP and Chief Legal Officer | Sale | 82 | $4.55 | $373.1 | SEC ↗ |
| May 19, 2026 | Thomas Desrosier | EVP and Chief Legal Officer | Sale | 79 | $7.53 | $594.87 | SEC ↗ |
| May 19, 2026 | Eric D. Shaff | Director | Sale | 259 | $7.53 | $2.0K | SEC ↗ |
| May 19, 2026 | Matthew R Henn | Chief Scientific Officer and EVP | Sale | 77 | $7.53 | $579.81 | SEC ↗ |
| May 19, 2026 | Kelly Brady | Chief Operating Officer, EVP | Sale | 59 | $7.53 | $444.27 | SEC ↗ |
| Feb 18, 2026 | Eric D. Shaff | Director | Sale | 259 | $8.47 | $2.2K | SEC ↗ |
| Feb 18, 2026 | Teresa L. Young | EVP, Chief Commercial & Strategy Officer | Sale | 75 | $8.47 | $635.25 | SEC ↗ |
| Feb 18, 2026 | Thomas Desrosier | Chief Legal Officer, EVP, Co-Chief Executive Officer, and Co-President | Sale | 78 | $8.47 | $660.66 | SEC ↗ |
| Feb 18, 2026 | Matthew R Henn | Chief Scientific Officer and EVP | Sale | 89 | $8.47 | $753.83 | SEC ↗ |
| Nov 18, 2025 | Teresa L. Young | EVP, Chief Commercial & Strategy Officer | Sale | 1.0K | $17.30 | $18.0K | SEC ↗ |
| Nov 18, 2025 | Eric D. Shaff | Director | Sale | 217 | $17.30 | $3.8K | SEC ↗ |
| Nov 18, 2025 | Thomas Desrosier | Chief Legal Officer, EVP, Co-Chief Executive Officer, and Co-President | Sale | 76 | $17.30 | $1.3K | SEC ↗ |
| Nov 18, 2025 | Matthew R Henn | Chief Scientific Officer and EVP | Sale | 1.3K | $17.30 | $21.7K | SEC ↗ |
| Aug 19, 2025 | Eric D. Shaff | Director | Sale | 217 | $16.65 | $3.6K | SEC ↗ |
| Aug 19, 2025 | Thomas Desrosier | Chief Legal Officer, EVP, Co-Chief Executive Officer, and Co-President | Sale | 76 | $16.65 | $1.3K | SEC ↗ |
| Aug 19, 2025 | Matthew R Henn | Chief Scientific Officer and EVP | Sale | 73 | $16.65 | $1.2K | SEC ↗ |
| Aug 19, 2025 | Teresa L. Young | EVP, Chief Commercial & Strategy Officer | Sale | 59 | $16.65 | $982.35 | SEC ↗ |
| May 19, 2025 | Teresa L. Young | EVP, Chief Commercial & Strategy Officer | Sale | 63 | $7.28 | $458.64 | SEC ↗ |
| May 19, 2025 | Eric D. Shaff | CEO and President | Sale | 220 | $7.28 | $1.6K | SEC ↗ |
| May 19, 2025 | Thomas Desrosier | Chief Legal Officer and EVP | Sale | 79 | $7.28 | $575.12 | SEC ↗ |
| May 19, 2025 | Matthew R Henn | Chief Scientific Officer and EVP | Sale | 77 | $7.28 | $560.56 | SEC ↗ |
| Feb 20, 2025 | Teresa L. Young | EVP, Chief Commercial & Strategy Officer | Sale | 3.3K | $0.81 | $2.7K | SEC ↗ |
Showing the 25 most recent of 96 Form 4 filings for Seres Therapeutics, Inc..
Most active MCRB insiders
- Eric D. Shaff15 filings
- Thomas Desrosier15 filings
- Matthew R Henn14 filings
- Teresa L. Young12 filings
- John G. Aunins9 filings
Ask anything about MCRB insider activity
Use Trabud's AI agent to query Seres Therapeutics, Inc.'s Form 4 history in plain English — "Show me MCRB CEO purchases this year" or compare it against any other ticker.
Open the AI agentMCRB insider trading FAQ
Are Seres Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Seres Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 16 sales ($54.9K) — net selling of $54.9K. Since January 2018, Trabud has recorded 96 Form 4 filings for MCRB: 2 buys ($47.5M) and 94 sells ($6.0M). Over the full record that is net buying of $41.5M.
How many insiders trade MCRB stock?
16 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Seres Therapeutics, Inc.. The most recent filing was accepted on Aug 18, 2026.
Where does Trabud get MCRB insider trading data?
All MCRB insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.